Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

Date: Sunday, November 13, 2016

Time: 2:30PM-4:00PM

Meeting: 2016 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 965

Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression

2:30PM-4:00PM: Abstract Number: 966

Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response

2:30PM-4:00PM: Abstract Number: 963

Treatment of Homocysteine Improves Urine Protein/Cr Ratio in SLE

2:30PM-4:00PM: Abstract Number: 964

Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment

2:30PM-4:00PM: Abstract Number: 968

Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment

2:30PM-4:00PM: Abstract Number: 967

Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].